-
Recent Posts
- Dementia and Disability (APPG on Dementia / Alzheimer’s Society)
- Scoping Dimensions of Dementia-Friendly Organisations (JGCR / IES / Alzheimer’s Society / RCN / JRF)
- Facts and Figures on Unmet Needs in Older People in England (Age UK)
- Statistics on Unpaid Carers in the UK: Carers Rights Day 2019 (Carers UK)
- Dementia Risk Factors Re-Explored / Confirmed (NIHR Signal / BMJ Open)
Archives
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Mirtazapine
Review of Non-Pharmacological Interventions for Dementia-Related Agitation: Including a Brief Analysis of the Risks and Benefits of Drug Treatments (Translational Psychiatry)
Summary A recently published literature review evaluates the best available evidence on the effectiveness of various non-pharmacological interventions for reducing dementia-related agitation. The author also briefly addresses current viewpoints on balancing the risks and benefits of pharmacotherapy in the management … Continue reading →
Posted in Acute Hospitals, Antipsychotics, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Local Interest, Management of Condition, Mental Health, Models of Dementia Care, New Cross Hospital, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, Systematic Reviews, UK, Universal Interest, Wolverhampton
|
Tagged ACADIA Pharmaceuticals, Agitation, Agitation and Aggression, Alternatives to Antipsychotic Drugs, Animal Assisted Therapy, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Aromatherapy, Arts and Music in Dementia, Atypical Antipsychotics, Avanir Pharmaceuticals Inc (California), Behavioural Alternatives to Antipsychotic Drugs, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, Behavioural Variant Frontotemporal Dementia (bvFTD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Carbamazepine, Citalopram, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Cognitive Behavioral Therapy, Dementia-Related Agitation, Department of Medicine: Royal Wolverhampton NHS Trust, Describe Investigate Create and Evaluate (DICE) Approach, East Kent Hospitals University NHS Foundation Trust, Electroconvulsive Therapy for Agitation and Aggression in Dementia, Improving the Quality of Life for People With Dementia, Interventions for BPSD, Intra-Cellular Therapies, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Memantine, Mirtazapine, Mood Disturbances, Multisensory Stimulation, Music Therapy, Music Therapy for BPSD, Music-Based Therapeutic Interventions, Nature Publishing Group, Neuroleptic Discontinuation, Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Non-Pharmacological Management of Symptoms, Non-Pharmacological Treatments, Otsuka Pharmaceuticals Limited, Pharmacological Treatments, Potential Harms of Antipsychotic Use, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Quetiapine, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, Simulated Presence Therapy (SPT), Simulated Presence Therapy for BPSD, Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME), Translational Psychiatry, Withdrawal of Neuroleptic Medications
|
Leave a comment
Dementia Revealed: Dementia Guide / Toolkit for GPs (NHS England / Department of Health / RCGP)
Summary NHS England has a commitment to improve dementia diagnosis rates. NHS England has published a guide to help GPs perform better on the timely diagnosis of dementia and to offer advice on post-diagnostic support for the person with the … Continue reading →
Posted in Alzheimer's Society, Antipsychotics, Charitable Bodies, Commissioning, Community Care, Delirium, Department of Health, Diagnosis, End of Life Care, Falls, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NHS England, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, UK, Universal Interest
|
Tagged 4AT Score, 4AT Screening Instrument for Rapid Initial Assessment of Delirium and Cognitive Impairment, Abbreviated Mental Test Score (AMTS), ACE III: Modified Addenbrooke’s Test, Activities of Daily Living (ADLs), Acute Change or Fluctuating Course, Addenbrooke's Cognitive Examination (ACE), Advance Decision to Refuse Treatment (ADRT), Advance Directives, Agitation, Alcohol Consumption, Alcohol Misuse, Alistair Burns: NHS England’s National Clinical Director for Dementia, Alternatives to Medication for Agitation, AMT4 (Abbreviated Mental Test - 4), Anticholinergic Drugs, Anticholinergics, Antipsychotics Limitation in Dementia, Antipsychotics: Neuroleptic Sensitivity, AT4 (Delirium Scale), Behavioural and Psychological Symptoms of Dementia (BPSD), Benefits Advice, Benzodiazepines, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Care Homes, Caregiver Assessments, Carers' Assessments, Clomethiazole, Coding of Dementia, Cognitive Stimulation Therapy (CST), Dementia and Alcohol, Dementia and Driving Guidance, Dementia Coding, Dementia Diagnosis Rates, Dementia Prevalence Calculator, Dementia Revealed: Dementia Guide for GPs, Dementia Toolkit for GP Commissioners, Dementia Toolkit for GPs, Deprivation of Liberty Safeguards (DoLS), Diagnosis and Assessment, Diagnosis and Referral, Diagnosis and Support, Diagnosis at Primary Care Level, Dr Elizabeth Barrett: Shires Health Care (Hardwick CCG), Driving, Driving and Dementia, Early Diagnosis, Fluctuation Assessment Scales, Fluctuations, General Practice, General Practice in England, General Practices, General Practitioner Assessment of Cognition (GPCOG), Geriatric Depression Scale, GPCog (The General Practitioner assessment of Cognition), GPs' Dementia Toolkit, IMCAs and Safeguarding, Improving Coding, Improving Dementia Diagnosis Rates, Improving General Practice, Inappropriate Use of Antipsychotics in Dementia, Independent Mental Capacity Advocates (IMCAs), Lasting Power of Attorney (LPoA), Lorazepam, Low Dose Antipsychotics, Managing Agitation, Memantine, Memory Clinics, Mini Mental State Examination (MMSE), Mirtazapine, Montreal Cognition Assessment (MOCA), NHS Continuing Care, NHS Hardwick CCG, Post-Diagnosis Support, Post-Diagnostic Support, Primary Care, Professor Alistair Burns, Quetiapine, RCGP, Risperidone, Rivastigmine, Royal College of General Practitioners (RCGP), Safeguarding Vulnerable Adults, Sertraline, Shires Health Care, Simon Stevens: Chief Executive of NHS England (2014-), Social Services, Support for Improving Dementia Diagnosis Rates, Temazepam, Timely Diagnosis, Trazodone, Voluntary Organisations, Wernicke-Korsakoff Syndrome, Zopiclone
|
Leave a comment
Recent Systematic Reviews and Meta-Analyses on Pharmacological Treatments
Some of the following articles are available freely, but a suitable Athens password, a journal subscription or one-off payment may be needed for access to the full-text of the other articles. The Bibliographic Citations Irwin, R.W. [and] Brinton, R.D. (2013). … Continue reading →
Posted in For Doctors (mostly), For Researchers (mostly), International, Management of Condition, Pharmacological Treatments, Systematic Reviews
|
Tagged Allopregnanolone, Alzheimer Neurobiology Center: Karolinska Institute, Alzheimer's Disease, Butyrylcholinesterase, Butyrylcholinesterase (BuChE), China, Cognitive Enhancers, Donepezil, EGb 761(®): Ginkgo Biloba Extract, France, Galantamine, Ginkgo Biloba Extract, Huperzine A, International Brain Research Foundation Inc.: USA, Karl-Landsteiner-Institut für Gedächtnis, Karolinska Institute, Lille Nord de France University, Marshall University Joan C. Edwards Medical School, Memantine, Memory Clinic: Sozialmedizinisches Zentrum Ost, Mirtazapine, Netherlands, Pharmacotherapy, Rivastigmine, Selected Systematic Reviews and Meta-Analyses, Selective Serotonin Reuptake Inhibitors (SSRIs), Sertraline, SNRI, SSRIs: Selective Serotonin Reuptake Inhibitors, Sweden, Systematic Reviews and Meta-Analyses, University of Amsterdam, University of British Columbia, University of Chinese Medicine: Beijing, University of Southern California, University of Sussex
|
Leave a comment
Sertraline or Mirtazapine Versus a Placebo for Treatment of Depression in Dementia (HTA-SADD Trial)
Summary This randomised control trial took place across nine English old-age psychiatry units. It examined the clinical effectiveness of sertraline and mirtazapine in reducing depression compared with a placebo. 326 patients with Alzheimer’s Disease (AD), depression and a Cornell Scale … Continue reading →
Posted in Acute Hospitals, Community Care, Depression, For Doctors (mostly), For Researchers (mostly), Management of Condition, Mental Health, National, NHS, Pharmacological Treatments, Quick Insights, Systematic Reviews, UK, Universal Interest
|
Tagged Alzheimer's Society, Antidepressants, Antidepressants for Depression in Dementia (HTA-SADD), Behavioral and Psychological Symptoms of Dementia (BPSD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Brighton and Sussex Medical School: University of Sussex, Burden of Dementia, Burden on Caregivers, Caregiving (Carers), Carers, Cornell Scale for Depression in Dementia (CSDD), Dementia Quality of Life (DEMQOL), DEMQOL-Proxy, Department of Community Based Medicine, Department of Mental Health Sciences: University College London, Department of Psychiatry: Liverpool University, Department of Psychiatry: University of Birmingham, Department of Psychiatry: University of Cambridge, Department of Psychiatry: University of Leicester, Department of Psychiatry: University of Southampton, Depression / Dysphoria, Depression in Alzheimer’s Disease Study-II (DIADS)-II, Depression in Dementia, Family Caregivers, Health Services and Population Research Department: King’s College London, Health Technology Assessment Study, HTA-SADD Trial, Hull York Medical School, Institute for Ageing and Health: Newcastle University, Institute of Psychiatry: King's College London, Institute of Rehabilitation: Hull York Medical School, Kings College London, Lancet, Liverpool University, Local Research Ethics Approvals (LREC), Mental Health and Neuroscience Clinical Trials Unit: King’s College London, Mirtazapine, Newcastle University, NIHR Health Technology Assessment Programme, Professor Sube Banerjee, Psychological Symptoms of Dementia (BPSD), Sertraline, Study of Antidepressants for Depression in Dementia (SADD), UK National Institute of Health Research HTA Programme, University College London, University of Birmingham, University of Cambridge, University of East Anglia, University of Leicester, University of Manchester, University of Southampton, University of Sussex, Venlafaxine, Watchful Waiting, Wolfson Centre for Age-Related Disease: King’s College London
|
Leave a comment
Evidence Update: Treatment of Depression in People With Dementia (NHS Evidence)
Summary Depression is common in dementia. It often causes distress, reduces quality of life, worsens cognitive and functional impairment, increases mortality, and also brings about stress and depression in carers. Earlier Guidance The NICE Clinical Guideline on Dementia (CG42) recommends … Continue reading →
Posted in Acute Hospitals, Community Care, Depression, For Doctors (mostly), Guidelines, Management of Condition, National, NHS Evidence, Pharmacological Treatments, Proposed for Next Newsletter, Quick Insights, Systematic Reviews, UK, Universal Interest
|
Tagged Antidepressants, Antidepressants for Depression in Dementia (HTA-SADD), Depression / Dysphoria, Depression in Older People, Mirtazapine, National Institute for Health and Clinical Excellence (NICE), NICE, NICE Clinical Guideline CG90, NICE–SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care, Professor Sube Banerjee, Sertraline
|
Leave a comment
Health Technology Assessment Study into the Use of Antidepressants for Depression in Dementia (HTA-SADD)
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 1, August 2011]. Summary Research into the efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, has found that these treatments … Continue reading →
Posted in Acute Hospitals, Community Care, Depression, For Doctors (mostly), For Researchers (mostly), In the News, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Antidepressants, Antidepressants for Depression in Dementia (HTA-SADD), Cornell Scale for Depression in Dementia (CSDD), Depression / Dysphoria, Health Technology Assessment Study, Mirtazapine, Sertraline, UK National Institute of Health Research HTA Programme
|
Leave a comment
